Alvimopan is a peripherally restricted mu-opioid receptor antagonist that accelerates gastrointestinal recovery after bowel resection surgery by blocking opioid-mediated motility suppression without crossing into the central nervous system. Simson Pharma's Alvimopan reference standard and impurities support stability-indicating testing for this perioperative GI therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Alvimopan Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.